124 Participants Needed

Neurodevelopmental Intervention for Preterm Infants

Recruiting at 1 trial location
MA
KS
Overseen ByKate St-Arneault, Ph.D (cand.)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

NeuroN-QI aims to evaluate the effects of an intervention consisting of periods of: 1) parents/preterm infants skin-to-skin contact and auditory stimulation by the parents's voice and 2) calm without manipulation with olfactory stimulation with breast milk in the incubator/bed both combined with appropriate light and noise levels to promote neurodevelopment preterm infants.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, infants still receiving certain medications like analgesics (pain relievers), sedatives, or paralyzing agents are excluded from the trial.

What data supports the effectiveness of the treatment NeuroN-QI, Nurturing and Quiet Intervention, SSC alone, Kangaroo Care, Skin-to-Skin Contact for preterm infants?

Research shows that Kangaroo Care, which involves skin-to-skin contact, can improve early cognitive development, neuromotor skills, and neurobehavioral performance in preterm infants. It also helps with stress response and breastfeeding success, indicating its positive impact on growth and development.12345

Is Kangaroo Care safe for preterm infants?

Kangaroo Care, which involves skin-to-skin contact between a parent and their preterm infant, is generally considered safe and beneficial. Research shows it supports better development, improves physiological stability, and has no reported negative effects.13678

How is the NeuroN-QI treatment different from other treatments for preterm infants?

NeuroN-QI, which includes Kangaroo Care (skin-to-skin contact), is unique because it emphasizes direct physical contact between the parent and infant, which has been shown to support early cognitive and neuromotor development in preterm infants. This approach is different from traditional care methods that may not involve as much parental involvement or sensory stimulation.1291011

Eligibility Criteria

This trial is for preterm infants born between 24 and nearly 34 weeks of gestational age, who are stable enough for skin-to-skin contact (SSC). Parents must commit to at least one SSC session per week with auditory stimulation until the infant reaches 36 weeks of gestational age. Mothers should be expressing breast milk for their infants. In case of twins, fathers can also participate.

Inclusion Criteria

For twin births (twin pregnancies), fathers will also be invited to participate in the study, so that both infants can participate in the study.
ready for SSC
I was born between 24 and 33 weeks of pregnancy.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Parents and preterm infants engage in skin-to-skin contact and auditory stimulation, followed by a calm period with olfactory stimulation, until the infants reach 36 weeks gestational age.

Until 36 weeks gestational age
At least 1 session weekly, ideally 3

Follow-up

Participants are monitored for neurodevelopmental outcomes and parental stress and anxiety levels.

18 months

Treatment Details

Interventions

  • NeuroN-QI
  • SSC alone
Trial Overview The NeuroN-QI intervention being tested includes parent-infant skin-to-skin contact paired with parental voice sounds and periods of calm without handling but with olfactory stimulation using breast milk. The environment's light and noise levels are controlled to aid neurodevelopment in preterm babies.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: NeuroN-QIExperimental Treatment1 Intervention
Randomized dyads in the experimental group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SSC) lasting 2 hours until the age of 36 weeks. Auditory sensory stimulation by mothers or fathers (reading a book) will be carried out during the first 10 minutes during the SSC sessions. The SSC will be followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
Group II: SSC aloneActive Control1 Intervention
Randomized dyads in the control group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SPC) lasting 2 hours until the corrected age of 36 weeks. During these sessions, light and noise levels will not be controlled or accompanied of auditory stimulation. SSC periods will not be followed by a calm and rest period with a olfactory stimulation.

Find a Clinic Near You

Who Is Running the Clinical Trial?

St. Justine's Hospital

Lead Sponsor

Trials
205
Recruited
87,300+

Findings from Research

In a study of 181 very preterm infants, those who received more skin-to-skin (STS) care during hospitalization showed significantly better neurodevelopmental scores at 12 months, suggesting that STS may enhance long-term outcomes.
Specifically, for every additional 20 minutes of STS care per day, infants experienced a notable increase of 10 points in their neurodevelopmental assessments, indicating a strong positive correlation between STS duration and developmental progress.
Inpatient Kangaroo Care Predicts Early Cognitive Development at 6 and 12 Months in Infants Born Very Preterm.Lazarus, MF., Marchman, VA., Brignoni-Pérez, E., et al.[2023]
In a study of 80 preterm infants, those placed in lateral decubitus (LD) position showed significantly better improvements in early neuromotor development compared to those in prone position (PP), with the LD group improving in 13 out of 16 assessed items.
The findings suggest that lateral positioning may enhance flexed posture and trunk alignment, which are beneficial for neuromotor development, but further long-term studies are needed to confirm these results.
Relationship between positioning of premature infants in Kangaroo Mother Care and early neuromotor development.Barradas, J., Fonseca, A., Guimarães, CL., et al.[2020]
Kangaroo care, which involves skin-to-skin contact between preterm infants and their parents, is safe and promotes better attachment between parents and infants, which can enhance nurturing behaviors.
While kangaroo care is associated with positive outcomes for growth and development in preterm infants, the specific impact on weight gain remains uncertain and requires further research.
Implications of kangaroo care for growth and development in preterm infants.Dodd, VL.[2016]

References

Inpatient Kangaroo Care Predicts Early Cognitive Development at 6 and 12 Months in Infants Born Very Preterm. [2023]
Relationship between positioning of premature infants in Kangaroo Mother Care and early neuromotor development. [2020]
Implications of kangaroo care for growth and development in preterm infants. [2016]
Longer duration of kangaroo care improves neurobehavioral performance and feeding in preterm infants: a randomized controlled trial. [2021]
Neurobehavioural assessment of skin-to-skin effects on reaction to pain in preterm infants: a randomized, controlled within-subject trial. [2008]
Understanding kangaroo care and its benefits to preterm infants. [2020]
Influence of holding practice on preterm infant development. [2021]
Skin-to-skin contact (Kangaroo Care) accelerates autonomic and neurobehavioural maturation in preterm infants. [2022]
Effectiveness of interventions during NICU hospitalization on the neurodevelopment of preterm infants: a systematic review protocol. [2022]
Kangaroo-mother care method and neurobehavior of preterm infants. [2016]
The effect of kangaroo mother care on aEEG activity and neurobehavior in preterm infants: a randomized controlled trial. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security